Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH (CandLE)

AstraZeneca

Status: Completed

Conditions: Essential Hypertension; Left Ventricular Hypertrophy

Study type: Observational

Funder types: Industry

Identifiers

NCT00607633

NIS-CGE-ATA-2007/2

Details and patient eligibility

About

The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

Enrollment: 686 patients

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• essential hypertension
• left ventricular hypertrophy
• under candesartan treatment

Exclusion Criteria:

Trial design

686 participants in 1 patient group

1

Description:

Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT